Who we are
Measurement and modulation of the gut microbiome in health and disease presents the opportunity to impact medicine in an entirely new and unexplored way.
Enterome is pioneering the development of novel drugs and diagnostics to support personalized therapies in microbiome-related diseases such as Inflammatory Bowel Diseases (IBD), metabolic diseases, and related disorders.
Enterome is also leading the development of new industry standards in gut microbiome quantitative and functional analysis. Opening up a new field of therapeutic targets discovery in the microbiome and allowing the innovative repositioning of existing compounds targeting this new organ.
Paris, France – 14 October 2014 Enterome named as a winner of the Entente Life Sciences Investment Forum 2014,...15 October 2014
Analysis of human gut microbiome provides new opportunities for liver cirrhosis diagnosis and treatment
Paris, France – 25 July 2014 New publication in Nature by international research team including Enterome scientific founder and Chief...29 July 2014